Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06724926 · ClinicalTrials.gov registry record · Phase 1
Concurrent Azeliragon With Craniospinal Irradiation
A Phase 1 study of Solid Tumor and High Grade Glioma, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06724926 is a Phase 1 study of Solid Tumor and High Grade Glioma that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 32 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06724926, a Phase 1 study of Solid Tumor and High Grade Glioma, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Single institution study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.
Conditions Studied
Interventions
- DRUG Azeliragon
- PROCEDURE CSI
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2031-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06724926
The ClinicalTrials.gov registry entry for NCT06724926 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Azeliragon is the first listed.
NCT06724926 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06724926 about?
NCT06724926 is a clinical study titled "Concurrent Azeliragon With Craniospinal Irradiation". Single institution study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.
What is the current status of trial NCT06724926?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-02-18. Estimated completion is 2031-01.
What conditions does trial NCT06724926 study?
This clinical trial studies the following conditions: Solid Tumor, High Grade Glioma, Leptomeningeal Metastasis.
What interventions are being tested in trial NCT06724926?
The interventions under investigation include: Azeliragon (DRUG), CSI (PROCEDURE).
Who is sponsoring clinical trial NCT06724926?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06724926 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.